Shaum Sridharan

Keywords Head and neck cancer tumor immunology clinical trial single-cell genomics T cell dynamics multispectral imaging combination immunotherapy PD-1 LAG-3 CTLA-4 Introduction While monoclonal antibodies (mAb) targeting the PD-1/PD-L1 pathway have transformed cancer treatment, durable responses are observed only in a minority of cancer patients.1,2,3,4 The limited clinical efficacy of cancer immunotherapy highlights the need to identify reliable markers that can predict responses to immune...

1 INTRODUCTION Poor treatment tolerance, including the failure to complete multimodality head and neck cancer (HNC) treatments or severe treatment-related toxicity, occurs in roughly 50% patients treated with curative intent.1, 2 Locoregionally advanced HNC often requires extirpative surgery and reconstruction which can render some patients too fragile to undergo further therapy with consequent worse oncologic and functional outcomes.3, 4 Despite advances in surgery and radiotherapy, poor...